Sarepta Therapeutics, Inc. which can be found using ticker (SRPT) have now 19 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 218 and 139 with the average target price sitting at $175.68. Given that the stocks previous close was at $149.07 this indicates there is a potential upside of 17.9%. The day 50 moving average is $133.03 while the 200 day moving average is $122.10. The company has a market capitalization of 13.68B. The stock price is currently at: 146.91 USD
The potential market cap would be $16,127,248,318 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 11.11 and a -11.88% return on assets.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
